Alyeska Investment Group
SLDB icon

Alyeska Investment Group’s Solid Biosciences SLDB Stock Holding History

Alyeska Investment Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8M Buy
2,280,484
+359
+0% +$2.72K 0.06% 321
2026
Q1 		$16.4M Buy
2,280,125
+597,320
+35% +$3.84M 0.05% 351
2025
Q4 		$9.49M Hold
1,682,805
– – 0.03% 396
2025
Q3 		$10.4M Buy
1,682,805
+41,984
+3% +$245K 0.03% 371
2025
Q2 		$7.99M Hold
1,640,821
– – 0.03% 377
2025
Q1 		$6.07M Buy
1,640,821
+1,294,450
+374% +$5.54M 0.02% 351
2024
Q4 		$1.39M Hold
346,371
– – 0.01% 482
2024
Q3 		$2.41M Sell
346,371
-100,000
-22% -$811K 0.01% 404
2024
Q2 		$2.53M Buy
446,371
+31,756
+8% +$284K 0.01% 394
2024
Q1 		$5.52M Sell
414,615
-222,664
-35% -$2.08M 0.03% 319
2023
Q4 		$3.91M Sell
637,279
-9,325
-1% -$29.8K 0.03% 326
2023
Q3 		$1.63M Hold
646,604
– – 0.01% 397
2023
Q2 		$3.39M Hold
646,604
– – 0.03% 366
2023
Q1 		$3.06M Buy
646,604
+106,457
+20% +$640K 0.03% 332
2022
Q4 		$2.89M Sell
540,147
-1
-0% -$7 0.03% 297
2022
Q3 		$3.74M Buy
540,148
+442,198
+451% +$4.46M 0.04% 283
2022
Q2 		$904K Buy
97,950
+10,000
+11% +$104K 0.01% 502
2022
Q1 		$1.58M Buy
87,950
+20,000
+29% +$353K 0.02% 457
2021
Q4 		$1.78M Buy
67,950
+9,040
+15% +$276K 0.02% 457
2021
Q3 		$2.11M Buy
58,910
+24,834
+73% +$1.05M 0.03% 490
2021
Q2 		$1.87M Hold
34,076
– – 0.02% 529
2021
Q1 		$2.83M Buy
+34,076
New +$3.77M 0.04% 414
2018
Q2 		– Sell
-7,457
Closed -$839K – 515
2018
Q1 		$839K Buy
+7,457
New +$2.52M 0.01% 399

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group's SLDB Position: Q2 2026 in Review

Alyeska Investment Group increased its Solid Biosciences (SLDB) stake by 0.02% in Q2 2026, buying an estimated $2.72K and bringing the position to 2,280,484 shares worth $22.8M. The position accounts for 0.06% of the portfolio, ranked #321.

Alyeska Investment Group first reported a position in SLDB in Q1 2018 and has held it in 23 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Alyeska Investment Group held 2,280,484 shares of Solid Biosciences worth $22.8M as of Q2 2026.
  • Alyeska Investment Group bought 359 Solid Biosciences shares in Q2 2026, an estimated $2.72K.
  • Solid Biosciences made up 0.06% of Alyeska Investment Group's portfolio in Q2 2026, its #321 holding.
  • Alyeska Investment Group first reported a position in Solid Biosciences in Q1 2018 and has held it in 23 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.